UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...
A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat ...
Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented ...
GlobalData on MSN1d
Gilead’s Livdelzi shows promise in PBC clinical trialThe analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.
Data presented at The Liver Meeting include adverse events as well as an assessment of patients’ relief of pruritus symptom scores when correlated to pharmacokinetics of TH104. Patients with ...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024PARIS, FRANCE, 18 ...
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback